• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110...

2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer

25 September 2012/in Uncategorised

2012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2012-09-25 16:00:102016-12-01 12:37:512012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors Link to: 2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors 2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory... Link to: DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia Link to: DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok